anti-CD3/anti-guanylate cyclase 2C bispecific T-cell engager (Helixon)

N/A

Report date: 2026/03/19 16:53:15

Base Information

Drug Nameanti-CD3/anti-guanylate cyclase 2C bispecific T-cell engager (Helixon)
Drug Alias NameGUCY2C x CD3 TCE
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionHeat-stable enterotoxin receptor modulatorsImmunostimulantsT cell surface glycoprotein CD3 modulators +[4] 
TargetsT cell surface glycoprotein CD3Heat-stable enterotoxin receptor
Therapy Area/IndicationsColorectal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesHelixon Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHelixon Ltd
Inactive CompaniesN/A
Active IndicationsColorectal Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A